dgwa.org | ANTISENSE RESEARCH REPORT
24741
post-template-default,single,single-post,postid-24741,single-format-standard,do-etfw,ajax_fade,page_not_loaded,,select-theme-ver-1.7.1,wpb-js-composer js-comp-ver-5.5.2,vc_responsive
15. January 2021 In DGWA

ANTISENSE RESEARCH REPORT

Corporate Connect has issued a research report on Antisense Therapeutics. The report increases the price target to AUD $0.43 or €0.26 in 12-months:

LINK: Antisense Therapeutics – Potential Competitor on the Canvas

Summary:

Sarepta Therapeutics’ (NASDAQ: SRPT) SRP-9001, a putative gene therapy (GT) for all Duchenne muscular dystrophy (DMD) patients has failed to demonstrate an improvement clinical function in a double- blind, randomised, placebo-controlled phase II trial in 41 patients. This event significantly improves the commercial prospects Antisense Therapeutics’ DMD therapy, ATL1102.